TROPION-Lung01 Study Design and Baseline demographics
Daiichi-Sankyo
Conclusions
•
•
•
TROPION-Breast01 demonstrated that Dato-DXd provides both improved efficacy and safety compared with
ICC for patients with HR+/HER2- disease
TROPION-Breast01 met its dual primary PFS endpoint, demonstrating statistically significant and clinically
meaningful improvement in PFS with Dato-DXd compared with ICC
-
-
Consistent PFS benefit observed across subgroups
Higher ORR with Dato-DXd and a trend at interim OS favouring Dato-DXd
Overall, Dato-DXd demonstrated a favourable and manageable safety profile, with no new safety signals
-
Most AESIs were grade 1-2
-
Patients receiving Dato-DXd had fewer grade ≥3 TRAES (less than half that with ICC), as well as fewer
TRAES leading to dose interruption/reduction compared with ICC
Results support Dato-DXd as a potential new therapeutic option
for patients with metastatic HR+/HER2- breast cancer
35View entire presentation